

The references below pertain to the comments by James P. Scanlan on the Action Plan for the Collection, Analysis, and Availability of Demographic Subgroup Data in Applications for Approval of FDA-Regulated Medical Products, May 16, 2014.

1. Scanlan JP. Race and mortality revisited. *Society* 2014;51 (July/Aug) (forthcoming)
2. Scanlan JP. Race and mortality. *Society* 2000;37(2):19-35 (reprinted in *Current* 2000 (Feb)): [http://www.jpscanlan.com/images/Race\\_and\\_Mortality.pdf](http://www.jpscanlan.com/images/Race_and_Mortality.pdf)
3. Scanlan JP. Divining difference. *Chance* 1994;7(4):38-9,48: [http://jpscanlan.com/images/Divining\\_Difference.pdf](http://jpscanlan.com/images/Divining_Difference.pdf)
4. Scanlan JP. Interpreting Differential Effects in Light of Fundamental Statistical Tendencies, presented at 2009 Joint Statistical Meetings of the American Statistical Association, International Biometric Society, Institute for Mathematical Statistics, and Canadian Statistical Society, Washington, DC, Aug. 1-6, 2009.  
PowerPoint Presentation : [http://www.jpscanlan.com/images/Scanlan\\_JSM\\_2009.ppt](http://www.jpscanlan.com/images/Scanlan_JSM_2009.ppt)  
Oral Presentation: [http://www.jpscanlan.com/images/JSM\\_2009\\_ORAL.pdf](http://www.jpscanlan.com/images/JSM_2009_ORAL.pdf)
5. Scanlan JP. Systematizing the analysis of effect heterogeneity requires rethinking some fundamentals. *Trials* June 1, 2011 (responding to Gabler NB, Naihua D, Liao D, et al. Dealing with heterogeneity of treatments effects: is the literature up to the challenge. *Trials* 2009,10:43): <http://www.trialsjournal.com/content/10/1/43/comments#512684>
6. Scanlan JP. Assessing heterogeneity of treatment effects in light of fundamental statistical tendencies. *Trials* May 26, 2011(responding to Kent DM, Rothwell PM, Ioannidis JPA, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. *Trials* 2010,11:85): <http://www.trialsjournal.com/content/11/1/85/comments#498686>
7. Problems in identifying interaction where groups have different base rates. *BMJ* Sept. 21, 2010 (responding to Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;326:219): Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;326:219): [http://www.BMJ.com/content/326/7382/219/reply#BMJ\\_el\\_241943](http://www.BMJ.com/content/326/7382/219/reply#BMJ_el_241943)
8. Scanlan JP. Rethinking the premises of subgroup analyses. *BMJ* June 7, 2010 (responding to Sun X, Briel M. Walter SD, and Guyatt GH. Is as subgroup effect believable? Updating criteria to evaluated the credibility of subgroup analyses. *BMJ* 2010;340:850-854): [http://www.BMJ.com/cgi/eletters/340/mar30\\_3/c117](http://www.BMJ.com/cgi/eletters/340/mar30_3/c117)
9. Subgroup Effects subpage of the Scanlan's Rule page of jpscanlan.com <http://www.jpscanlan.com/scanlansrule/subgroupeffects.html>
10. Interactions by Age subpage of the Scanlan's Rule page of jpscanlan.com <http://jpscanlan.com/scanlansrule/interactionsbyage.html>

11. Life Tables Illustrations subpage of Scanlan's Rule page of jpscanlan.com:  
<http://jpscanlan.com/scanlansrule/lifetableillustrations.html>
12. Framingham Illustrations subpage of Scanlan's Rule page of jpscanlan.com  
<http://jpscanlan.com/scanlansrule/framinghamillustrations.html>
13. Reporting Heterogeneity subpage of the Measuring Health Disparities page of jpscanlan.com  
<http://jpscanlan.com/measuringhealthdisp/reportingheterogeneity.html>
14. Illogical Premises subpage of Scanlan's Rule page of jpscanlan.com  
<http://jpscanlan.com/scanlansrule/illogicalpremises.html>
15. Ratio measures are not transportable. BMJ Nov. 11, 2011 (responding to Schwartz LS, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals: structured review of underlying absolute risks. BMJ 2006;333:1248-1252):  
<http://www.BMJ.com/content/333/7581/1248?tab=responses>
16. Scanlan JP. Goodbye to the rate ratio. BMJ Feb. 25, 2013 (responding to Hingorani AD, van der Windt DA, Riley RD, et al. Prognosis research strategy (PROGRESS) 4: Stratified medicine research. BMJ2013;346:e5793): <http://www.BMJ.com/content/346/BMJ.e5793/rr/632884>
17. Inevitability of Interaction subpage of Scanlan's Rule page of jpscanlan.com  
<http://jpscanlan.com/scanlansrule/inevitableinteraction.html>
18. Scanlan JP. The inevitability of interaction. BMJ Dec. 19, 2011 (responding to Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219):  
Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219): <http://www.BMJ.com/content/326/7382/219?tab=responses>